212 related articles for article (PubMed ID: 27698946)
1. A New Concept of Enhancing Immuno-Chemotherapeutic Effects Against B16F10 Tumor
Yang Y; Tai X; Shi K; Ruan S; Qiu Y; Zhang Z; Xiang B; He Q
Theranostics; 2016; 6(12):2141-2160. PubMed ID: 27698946
[TBL] [Abstract][Full Text] [Related]
2. The nanoparticulation by octaarginine-modified liposome improves α-galactosylceramide-mediated antitumor therapy via systemic administration.
Nakamura T; Yamazaki D; Yamauchi J; Harashima H
J Control Release; 2013 Oct; 171(2):216-24. PubMed ID: 23860186
[TBL] [Abstract][Full Text] [Related]
3. A pH-responsive cell-penetrating peptide-modified liposomes with active recognizing of integrin αvβ3 for the treatment of melanoma.
Shi K; Li J; Cao Z; Yang P; Qiu Y; Yang B; Wang Y; Long Y; Liu Y; Zhang Q; Qian J; Zhang Z; Gao H; He Q
J Control Release; 2015 Nov; 217():138-50. PubMed ID: 26368312
[TBL] [Abstract][Full Text] [Related]
4. Enhanced chemo-immunotherapy against melanoma by inhibition of cholesterol esterification in CD8
Li M; Yang Y; Wei J; Cun X; Lu Z; Qiu Y; Zhang Z; He Q
Nanomedicine; 2018 Nov; 14(8):2541-2550. PubMed ID: 30193815
[TBL] [Abstract][Full Text] [Related]
5. Tumor-Targeted Chemoimmunotherapy with Immune-Checkpoint Blockade for Enhanced Anti-Melanoma Efficacy.
Li M; Yang Y; Xu C; Wei J; Liu Y; Cun X; Yu Q; Tang X; Yin S; Zhang Z; He Q
AAPS J; 2019 Jan; 21(2):18. PubMed ID: 30635795
[TBL] [Abstract][Full Text] [Related]
6. Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide.
Chen X; Wang X; Wang Y; Yang L; Hu J; Xiao W; Fu A; Cai L; Li X; Ye X; Liu Y; Wu W; Shao X; Mao Y; Wei Y; Chen L
J Control Release; 2010 Jul; 145(1):17-25. PubMed ID: 20307599
[TBL] [Abstract][Full Text] [Related]
7. Dual receptor recognizing liposomes containing paclitaxel and hydroxychloroquine for primary and metastatic melanoma treatment via autophagy-dependent and independent pathways.
Yin S; Xia C; Wang Y; Wan D; Rao J; Tang X; Wei J; Wang X; Li M; Zhang Z; Liu J; He Q
J Control Release; 2018 Oct; 288():148-160. PubMed ID: 30099017
[TBL] [Abstract][Full Text] [Related]
8. Antitumor effect of iRGD-modified liposomes containing conjugated linoleic acid-paclitaxel (CLA-PTX) on B16-F10 melanoma.
Du R; Zhong T; Zhang WQ; Song P; Song WD; Zhao Y; Wang C; Tang YQ; Zhang X; Zhang Q
Int J Nanomedicine; 2014; 9():3091-105. PubMed ID: 25028548
[TBL] [Abstract][Full Text] [Related]
9. Peptide ligand and PEG-mediated long-circulating liposome targeted to FGFR overexpressing tumor in vivo.
Cai L; Wang X; Wang W; Qiu N; Wen J; Duan X; Li X; Chen X; Yang L; Qian Z; Wei Y; Chen L
Int J Nanomedicine; 2012; 7():4499-510. PubMed ID: 22923988
[TBL] [Abstract][Full Text] [Related]
10. A pH-responsive α-helical cell penetrating peptide-mediated liposomal delivery system.
Zhang Q; Tang J; Fu L; Ran R; Liu Y; Yuan M; He Q
Biomaterials; 2013 Oct; 34(32):7980-93. PubMed ID: 23891517
[TBL] [Abstract][Full Text] [Related]
11. Losartan loaded liposomes improve the antitumor efficacy of liposomal paclitaxel modified with pH sensitive peptides by inhibition of collagen in breast cancer.
Xia T; He Q; Shi K; Wang Y; Yu Q; Zhang L; Zhang Q; Gao H; Ma L; Liu J
Pharm Dev Technol; 2018 Jan; 23(1):13-21. PubMed ID: 27884084
[TBL] [Abstract][Full Text] [Related]
12. PEG liposomalization of paclitaxel improved its in vivo disposition and anti-tumor efficacy.
Yoshizawa Y; Kono Y; Ogawara K; Kimura T; Higaki K
Int J Pharm; 2011 Jun; 412(1-2):132-41. PubMed ID: 21507344
[TBL] [Abstract][Full Text] [Related]
13. Temporary suppression the sequestrated function of host macrophages for better nanoparticles tumor delivery.
Hao J; Han T; Wang M; Zhuang Q; Wang X; Liu J; Wang Y; Tang H
Drug Deliv; 2018 Nov; 25(1):1289-1301. PubMed ID: 29869519
[TBL] [Abstract][Full Text] [Related]
14. Comparison of two methods for tumour-targeting peptide modification of liposomes.
Huang SQ; Zhang HM; Zhang YC; Wang LY; Zhang ZR; Zhang L
Acta Pharmacol Sin; 2023 Apr; 44(4):832-840. PubMed ID: 36271156
[TBL] [Abstract][Full Text] [Related]
15. Tyroservatide-TPGS-paclitaxel liposomes: Tyroservatide as a targeting ligand for improving breast cancer treatment.
Jin X; Li M; Yin L; Zhou J; Zhang Z; Lv H
Nanomedicine; 2017 Apr; 13(3):1105-1115. PubMed ID: 27845234
[TBL] [Abstract][Full Text] [Related]
16. Tumor-penetrating codelivery of siRNA and paclitaxel with ultrasound-responsive nanobubbles hetero-assembled from polymeric micelles and liposomes.
Yin T; Wang P; Li J; Wang Y; Zheng B; Zheng R; Cheng D; Shuai X
Biomaterials; 2014 Jul; 35(22):5932-43. PubMed ID: 24746965
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and evaluation of a paclitaxel-binding polymeric micelle for efficient breast cancer therapy.
Xiang J; Wu B; Zhou Z; Hu S; Piao Y; Zhou Q; Wang G; Tang J; Liu X; Shen Y
Sci China Life Sci; 2018 Apr; 61(4):436-447. PubMed ID: 29572777
[TBL] [Abstract][Full Text] [Related]
18. Improved anticancer effects of albumin-bound paclitaxel nanoparticle via augmentation of EPR effect and albumin-protein interactions using S-nitrosated human serum albumin dimer.
Kinoshita R; Ishima Y; Chuang VTG; Nakamura H; Fang J; Watanabe H; Shimizu T; Okuhira K; Ishida T; Maeda H; Otagiri M; Maruyama T
Biomaterials; 2017 Sep; 140():162-169. PubMed ID: 28651144
[TBL] [Abstract][Full Text] [Related]
19. Long-circulating self-assembled cholesteryl albumin nanoparticles enhance tumor accumulation of hydrophobic anticancer drug.
Battogtokh G; Kang JH; Ko YT
Eur J Pharm Biopharm; 2015 Oct; 96():96-105. PubMed ID: 26212785
[TBL] [Abstract][Full Text] [Related]
20. High Tumor Penetration of Paclitaxel Loaded pH Sensitive Cleavable Liposomes by Depletion of Tumor Collagen I in Breast Cancer.
Zhang L; Wang Y; Yang Y; Liu Y; Ruan S; Zhang Q; Tai X; Chen J; Xia T; Qiu Y; Gao H; He Q
ACS Appl Mater Interfaces; 2015 May; 7(18):9691-701. PubMed ID: 25845545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
